

## MCMB Dashboard (FY2017/18)

### Mission statement

The Molecular and Cellular Medicine Board is responsible for MRC's investments in understanding the molecular and cellular mechanisms that underpin biological function in human health and disease, and supporting the translation of knowledge towards new diagnosis and treatment, and changes to policy and practice. The Board seeks to extend our understanding of structure-function insights of molecules and complexes, how the cellular environment functions during development and mature states, the relationship between genotype and phenotype, and how systems respond to external insults (e.g. drugs and toxins) and disease states. The Board leads MRC's investments in cancer and haematology, from fundamental discovery science to epidemiology, experimental medicine and early translation.

### Award rate by Research Board

(by number and % across a 3yr average)

Grant type	IIB	MCMB	NMHB	PSMB
Research	28/158 18%	34/184 18%	32/215 15%	22/177 13%
NIRGs	7/22 31%	4/23 19%	5/32 16%	6/22 29%
Programme	5/9 52%	6/20 28%	5/14 37%	6/12 49%
Partnership	0/3 0%	4/9 44%	4/12 33%	4/14 29%
Overall Award Rate	21%	22%	17%	17%


### Partnership funding

- [UK Stem Cell Bank](#) (MRC £2m; BBSRC £200k)
- [Human Developmental Biology Resource](#) (MRC and Wellcome, £2m each)
- MCMB jointly funded grants with EPSRC and BBSRC (total contribution £241k).

### Key investment areas / messages

- Major areas of spend in FY2016/17 (latest data available) continue to be in cancer (£43m), cell biology (£34m) and structural biology (£28m), and genetics/genomics (£39m).
- Spikes in expenditure in cancer, genetics and regenerative medicine over the last few years reflect major capital investments (e.g. clinical research infrastructure in 2015/16). Beyond this, cancer spend appears on an upward trend. The recent fall in structural biology and developmental biology expenditure is an artefact of the transition of research from NIMR to the Crick with the latter not yet captured within MRC's portfolio. Spend in other areas appears steady.
- ODA commitment in FY2017/18 was £419k.
- MCMB and Strategy Board supported IMPC and UK genetic mouse services (£2m, 2.5 years).

### Annual spend (£m) across categories



### Major strategic investments in FY2017/18:

- **Human Genetics Unit** (£53.2m, 5 yrs): MRC's largest Unit that combines human/clinical genetics, population studies, model organism, cellular systems, and computation to explore the role of genetics in health and disease. The related Institute of Genetics and Molecular Medicine investment (£2m, 5 yrs) brings together local complementary interests in cancer and genomics to provide strategic added value
- **Protein Phosphorylation and Ubiquitylation Unit** (£25.6m, 5 yrs): a distinctive, and strategically important investment exploring signal pathways central to cellular function and drug targeting, with major partnerships with pharma
- **Toxicology Unit** (£35.1m 5 yrs): a unique UK investment exploring mechanistic links between tox exposures and disease. Major new strategic partnership with the University of Cambridge as part of its relocation from Leicester. Co-funding from Cambridge and AZ/GSK to help support 5 new programmes, fellowships and PhDs
- **UK Stem Cell Bank** (£2.2m, 3 years): Unique national resource providing a collection of research and clinical-grade embryonic stem cell lines for research and regenerative medicine. Funding will support cell line characterisation to inform uptake and use.

### MCMB Opportunities

- Understanding dynamic biological systems
- Exposures, biological mechanisms and disease
- Radiation oncology and biology